Benoît Heid-Picard1, Béatrix Cochand-Priollet2, Flore Rozenberg3, David Giang-Phang4, Jean-Paul Viard4, Valentina La Torre5, Jade Ghosn1,4. 1. Department of Infectious and Tropical Diseases, Hôpital Bichat-Claude Bernard, Assistance Publique des Hôpitaux de Paris, Université de Paris, Paris, France. 2. Department of Pathology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université de Paris, Paris, France. 3. Department of Virology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université de Paris, Paris, France. 4. Departement of Infectious and Tropical Diseases, Hôpital Hôtel-Dieu, Assistance Publique des Hôpitaux de Paris, Université de Paris, Paris, France. 5. Diagnosis and Therapeutic Center, Hôpital Hôtel-Dieu, Assistance Publique-Hôpitaux de Paris, Université de Paris, Paris, France.
Abstract
OBJECTIVES: Anal cancer, usually driven by an oncogenic Human Papillomavirus, remains a leading cause of morbidity in men who have sex with men (MSM) living with HIV, despite combined antiretroviral therapy. Various recommendations advocate to perform regular examination and proctologist-performed samples to anticipate this risk and treat locally before cancer occurrence, an efficient strategy which has the drawback of requiring the proctologist's availability. This study evaluates the acceptability, feasibility, and efficiency of self-performed samples to screen for HPV-infection and HPV-related anal dysplasia among MSM living with HIV followed in Hôtel-Dieu Hospital. METHODS: Between February 2015 and June 2015, MSM living with HIV and referred to the day-care hospital were offered to perform an anal self-sampling for cytologic and virologic evaluation. A self-sampling kit was provided, and a tutorial video was shown. A subset of participants had a proctology appointment after they did the self-sampling, and thus had a clinical examination and an anal swab sampling performed by the proctologist, using the same sampling material. RESULTS: Anal self-sampling was offered to 103 patients, and 100 accepted. Sixty-three samples were interpretable, of which 36 (57%) were normal and 27 (43%) showed abnormal results. Virologic analysis was performed for 60 (95%) interpretable samples: 50/60 (83%) of them were positive for HPV. Among HPV-carrier patients, 42/50 (84%) were infected with at least one HR-HPV. Twenty patients had a proctologist consultation. All clinician-performed samples were interpretable and 14 (70%) self-samples were interpretable. CONCLUSIONS: This study highlights the acceptable accuracy of self-sampling screening method among MSM living with HIV and try out its acceptability and feasibility as a secondary prevention device. Although it cannot replace a proctologist consultation for high risk patients, self-sampling should be studied further as one of the ways of screening for anal cancer among low-risk outpatients.
OBJECTIVES: Anal cancer, usually driven by an oncogenic Human Papillomavirus, remains a leading cause of morbidity in men who have sex with men (MSM) living with HIV, despite combined antiretroviral therapy. Various recommendations advocate to perform regular examination and proctologist-performed samples to anticipate this risk and treat locally before cancer occurrence, an efficient strategy which has the drawback of requiring the proctologist's availability. This study evaluates the acceptability, feasibility, and efficiency of self-performed samples to screen for HPV-infection and HPV-related anal dysplasia among MSM living with HIV followed in Hôtel-Dieu Hospital. METHODS: Between February 2015 and June 2015, MSM living with HIV and referred to the day-care hospital were offered to perform an anal self-sampling for cytologic and virologic evaluation. A self-sampling kit was provided, and a tutorial video was shown. A subset of participants had a proctology appointment after they did the self-sampling, and thus had a clinical examination and an anal swab sampling performed by the proctologist, using the same sampling material. RESULTS: Anal self-sampling was offered to 103 patients, and 100 accepted. Sixty-three samples were interpretable, of which 36 (57%) were normal and 27 (43%) showed abnormal results. Virologic analysis was performed for 60 (95%) interpretable samples: 50/60 (83%) of them were positive for HPV. Among HPV-carrier patients, 42/50 (84%) were infected with at least one HR-HPV. Twenty patients had a proctologist consultation. All clinician-performed samples were interpretable and 14 (70%) self-samples were interpretable. CONCLUSIONS: This study highlights the acceptable accuracy of self-sampling screening method among MSM living with HIV and try out its acceptability and feasibility as a secondary prevention device. Although it cannot replace a proctologist consultation for high risk patients, self-sampling should be studied further as one of the ways of screening for anal cancer among low-risk outpatients.
Authors: Thomas M Lampinen; Keith Chan; Aranka Anema; Janet Kornegay; Robert S Hogg; Francois Coutlee Journal: Clin Infect Dis Date: 2006-01-15 Impact factor: 9.079
Authors: Dorothy A Machalek; Mary Poynten; Fengyi Jin; Christopher K Fairley; Annabelle Farnsworth; Suzanne M Garland; Richard J Hillman; Kathy Petoumenos; Jennifer Roberts; Sepehr N Tabrizi; David J Templeton; Andrew E Grulich Journal: Lancet Oncol Date: 2012-03-23 Impact factor: 41.316
Authors: Courtney Covert; Lili Ding; Darron Brown; Eduardo L Franco; David I Bernstein; Jessica A Kahn Journal: Hum Vaccin Immunother Date: 2019-02-20 Impact factor: 3.452
Authors: T R H Read; L Vodstrcil; A E Grulich; C Farmer; C S Bradshaw; M Y Chen; S Tabrizi; J S Hocking; J Anderson; C K Fairley Journal: HIV Med Date: 2013-04-16 Impact factor: 3.180
Authors: C M Vajdic; M T van Leeuwen; F Jin; G Prestage; G Medley; R J Hillman; M P Stevens; L P Botes; I Zablotska; S N Tabrizi; A E Grulich Journal: Sex Transm Infect Date: 2009-04-01 Impact factor: 3.519
Authors: Thomas M Lampinen; Mary Lou Miller; Keith Chan; Aranka Anema; Dirk van Niekerk; Arn J Schilder; Robert Taylor; Robert S Hogg Journal: Cytojournal Date: 2006-03-20 Impact factor: 2.091
Authors: Bryan A Kutner; Jane M Simoni; Will DeWitt; Michael M Gaisa; Theodorus G M Sandfort Journal: LGBT Health Date: 2022-02-07 Impact factor: 5.150